pubmed,org ristori + bcg and consult the italian ministry of health also google ms + bcg and ms + ristori
congress is a silly bunch but it is time to recall an experience with andrew drexler supreme court justice sotomayor's physian at the time and once at mout sinai in ny ny
drexler was conducting a trial of symlin subsequent to an earlier trial of same elsewhere
all the participsnts said the drug made them not hungry! as well as lowering blood sugar
any participant in the double blind trialimmeciately sensed the market potential of the stuff.
the compsny replaced 10 ml visls with pens to make money
the stock was low and went up
any gambling fool might have placed good bet
sadly sotomayor's views on the work of the great white woman from boston dr denise l faustmsn will remain between her and her clerks as she mades her decisions privately. she is a diabetic
congressman and supreme court members call em as the see them but both might think of the greater good that might be achieved with the work of the great ehite woman denise l faustman and the italian healer g ristori
the us is the land of short quick and stupid and nearsighted because we elect people just like us?
New York Congressman Chris Collins Arrested on Insider-Trading Charges
Rep. Collins is accused of passing drug-trial tip to his son for him to trade on
Rep. Christopher Collins (R., N.Y.) leaves federal court in Manhattan on Wednesday following his arraignment on insider-trading charges. PHOTO: SPENCER PLATT/GETTY IMAGES
Rep. Christopher Collins, a Republican congressman from New York, was arrested Wednesday and charged with participating in an insider-trading scheme to sell the shares of an Australian biotechnology company before the public disclosure of a failed drug trial.
Federal prosecutors in Manhattan accused Rep. Collins, 68 years old, of tipping off his son last summer about the results of a multiple-sclerosis drug trial completed by Innate Immunotherapeutics Ltd. , a biotechnology company based in Sydney. Rep. Collins was a member of Innate’s board of directors and one of the company’s largest shareholders, holding approximately 16.8% of its stock, the indictment said.
Rep. Collins, who serves the 27th district in western New York near Buffalo and Rochester, was the first member of Congress to endorse Donald Trump during the 2016 presidential campaign. Once considered a backbencher in the House, Rep. Collins’s stature grew after Mr. Trump won the GOP nomination.
According to the indictment, Rep. Collins passed the confidential results to his son, Cameron Collins, so he could trade on the tip. Prosecutors say his son sold nearly 1.4 million Innate shares and gave the information to at least four individuals, including his fiancée and her father, Stephen Zarsky.
Mr. Zarsky then sold all of his Innate shares and shared the tip with at least three other individuals, including his brother and sister, before the public release of the trial results, according to the indictment.
Tom Price, the former secretary of health and human services, was also an investor in Innate and has previously said he bought shares in the company after hearing about it from Rep. Collins. Dr. Price sold his Innate shares upon taking the cabinet post and wasn’t a shareholder in June 2017 when the clinical-trial results were announced.
Several other Republicans in Congress held stock in the company, according to financial disclosures.
Innate publicly announced the failed drug trial after U.S. markets had closed on June 26, 2017. The next day, Innate’s stock dropped more than 90%. In total, the trades allowed the defendants and alleged co-conspirators to avoid more than $768,000 in losses, the indictment said.
“I believe I acted properly and within the law at all times,” Rep. Collins said at a press conference Wednesday night, saying he had also followed “all rules and ethical guidelines” for members of Congress.
He said he would remain on the ballot in November, running for re-election.
Cameron Collins and Mr. Zarsky were also charged Wednesday. Their lawyers didn’t immediately respond to a request for comment.
All three men pleaded not guilty at their arraignment in Manhattan federal court, and each was released on $500,000 bond.
Innate’s primary business has been developing an experimental drug to treat an advanced form of multiple sclerosis, the subject of the failed clinical trial. The company’s chief executive told investors in 2016 that its future would depend on the drug’s success.
Rep. Collins has been an investor in the company for more than 15 years, The Wall Street Journal previously reported.
On Wednesday, House Speaker Paul Ryan (R., Wis.) removed Rep. Collins from his perch on the powerful House Energy and Commerce Committee and called on the bipartisan House Ethics Committee to investigate the lawmaker’s conduct.
Four days before the public release of the drug clinical-trial results, Innate’s chief executive sent an email to the company’s board saying the trial had failed, the indictment said. Rep. Collins, who was attending the Congressional Picnic at the White House, allegedly responded to the email: “Wow. Makes no sense. How are these results even possible??”
Less than a minute later, prosecutors said, he made multiple calls to his son.
His son and his fiancée, who is identified only as “co-conspirator 1” in the indictment, then drove to the home of her father, Mr. Zarsky, to alert them of the results, prompting Mr. Zarsky and his wife to sell all of their Innate shares, prosecutors said. The next morning, Mr. Zarsky allegedly disseminated the trial results to others, including calling his sister to tell her she “needed to sell her Innate shares and not to ask why,” the indictment said.
The three men were charged with 10 criminal counts, including securities fraud, wire fraud and making false statements during interviews with the Federal Bureau of Investigation. The Securities and Exchange Commission also sued Rep. Collins, his son and Mr. Zarsky in a civil action filed in Manhattan federal court.
Prosecutors said Rep. Collins didn’t make any trades himself. At the time he found out about Innate’s failed drug trial, he was already being investigated for his promotion of the biotech company by the Office of Congressional Ethics, a nonpartisan body that investigates allegations of wrongdoing by members of Congress.
According to the congressman’s 2016 financial disclosure report, he held a stake in Innate valued at the time between $25 million and $50 million.
Other Republican lawmakers—including Rep. Markwayne Mullin of Oklahoma, Rep. John Culberson of Texas, and Rep. Mike Conaway of Texas—have also purchased stakes in the company, according to financial disclosures.
Rep. Mullin still owns the stock, a spokeswoman said.
Rep. Culberson has previously said he sold his stake in the company on June 12, 2017, which is 10 days before Rep. Collins allegedly shared the drug trial results with his son. He said he sold “simply to cut my losses,” according to a statement.
Rep. Conaway sold his stock in November 2017, a spokeswoman said.
In October, the OCE issued a report saying Rep. Collins used his public office to benefit Innate and may have shared nonpublic information with other investors. The office referred the case to the House Ethics Committee and said the conduct may have violated federal law.
The House Ethics Committee, which is evenly divided between Republican and Democratic members of Congress, has an ongoing investigation into Rep. Collins, but it hasn’t set up an investigative subcommittee to look into the allegations.
The arrest of Rep. Collins will likely tighten his re-election campaign fending off Democratic challenger Nate McMurray, the town supervisor of Grand Island. The nonpartisan Cook Political Report on Wednesday changed its rating of the district, moving it to “likely Republican” from “solid Republican.”
Republicans still hold an advantage in the district, which Mr. Trump won with more than 59% of the vote in 2016. And Mr. McMurray had less than $82,000 in cash on hand at the end of June, compared with Rep. Collins’s $1.3 million in cash on hand at the same point, according to Federal Election Commission records.
“These are very serious charges,” said Matt Gorman, spokesman for House Republicans’ campaign arm. “We will let the facts come to light and trust the judicial system as we continue to assess his reelection campaign.”
—Rebecca Davis O’Brien and Andrew Duehren contributed to this article.
